Cancer Vaccine Partnering Agreements -





Published: December 2014 | Pages: 294 | Version: 6

 

The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

 

  • Trends in cancer vaccine partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Cancer vaccine partnering contract documents
  • Top cancer vaccine deals by value

 

The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides an understanding and analysis of how and why companies enter cancer vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

 

This report contains over 160 links to online copies of actual cancer vaccine deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of cancer vaccine dealmaking and business activities.

 

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in cancer vaccine dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms by stage of development.It also provides the number of deals entered by top 50 big pharma, big biotech and most active dealmakers in cancer vaccine partnering.

                    

Chapter 3 provides a review of the leading cancer vaccine deals since 2009. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive and detailed review of all cancer vaccine partnering deals signed and announced since January 2009.The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes adjuvant deals and alliances.

 

The report also includes numerous tables and figures that illustrate the trends and activities in cancer vaccine partnering and dealmaking since 2009.

                                                  

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cancer vaccine technologies and products.

 

 Report scope 

 

Cancer Vaccine Partnering Agreements is intended to provide the reader with an in-depth understanding and access to cancer vaccine trends and structure of deals entered into by leading companies worldwide.

 

Cancer Vaccine Partnering Agreements includes:

 

  • Trends in cancer vaccine dealmaking in the biopharma industry since 2009
  • Analysis of cancer vaccine deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 160 cancer vaccine deal records
  • The leading cancer vaccine deals by value since 2009
  • Includes adjuvant and drug delivery deals and alliances since 2009

 

In Cancer Vaccine Partnering Agreements, the available deals are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific oncology therapy target

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The Cancer Vaccine Partnering Agreements report provides comprehensive access to available deals and contract documents for over 160 cancer vaccine deals. Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?


 

 

Chapter 1 – Introduction 

 

Chapter 2 – Trends in cancer vaccine dealmaking 

 

2.1. Introduction

2.2. Cancer vaccine partnering over the years

2.3. Big pharma cancer vaccine dealmaking activity

2.3. Big biotech cancer vaccine dealmaking activity

2.4. Most active in cancer vaccine partnering

2.5. Cancer vaccine partnering by deal type

2.6. Cancer vaccine partnering by stage of development

2.7. Cancer vaccine partnering by cancer indication

2.8. Disclosed deal terms for cancer vaccine partnering

2.8.1 Cancer vaccine partnering headline values

2.8.2 Cancer vaccine deal upfront payments

2.8.3 Cancer vaccine deal milestone payments

2.8.4 Cancer vaccine royalty rates

2.9. The anatomy of cancer vaccine partnering

2.9. The anatomy of a cancer vaccine deal

2.9. a. Case study 1: Stemline Therapeutics, University of Pittsburgh- March 30 2012

2.9. b. Case study 2: Agenus Bio, NewVac: Dec 19, 2011

 

Chapter 3 – Leading cancer vaccine deals 

 

3.1. Introduction

3.2. Top cancer vaccine deals by value

 

Chapter 4 – Cancer vaccine dealmaking directory 

 

4.1. Introduction

4.2. Cancer vaccine deals by company A-Z

4.3. Cancer vaccine deals by stage of development

4.4. Cancer vaccine deals by deal type

4.5. Cancer vaccine deals by oncology therapy area

4.6. Cancer deals by vaccines and adjuvant technology

 

Chapter 5 – Partnering resource center 

 

5.1. Online partnering

5.2. Partnering events

5.3. Further reading on dealmaking

 

Appendices 

 

Appendix 1 – Deal type definitions

About Wildwood Ventures

Current Partnering

Current Agreements

Recent report titles from CurrentPartnering

Order Form – Upgrades to subscription access products

Order Form – Technology Reports

 

Table of figures 

 

Figure 1: Cancer vaccine partnering since 2009

Figure 2: Big pharma – top 50 – cancer vaccine deals 2009 to 2014

Figure 3: Big pharma cancer vaccine deal frequency – 2009 to 2014

Figure 4: Big biotech – top 50 – cancer vaccine deals 2009 to 2014

Figure 5: Big biotech cancer vaccine deal frequency – 2009 to 2014

Figure 6: Active cancer vaccine dealmaking activity– 2009 to 2014

Figure 7: Cancer vaccine partnering by deal type since 2009

Figure 8: Cancer vaccine partnering by stage of development since 2009

Figure 9: Cancer vaccine partnering by oncology target since 2009

Figure 10: Cancer vaccine deals with a headline value – by stage of development

Figure 11: Cancer vaccine deal headline value distribution, US$million – discovery stage

Figure 12: Cancer vaccine deal headline value distribution, US$million – preclinical stage

Figure 13: Cancer vaccine deal headline value distribution, US$million – phase I stage

Figure 14: Cancer vaccine deal headline value distribution, US$million – phase II stage

Figure 15: Cancer vaccine deal headline value distribution, US$million – phase III stage

Figure 16: Cancer vaccine deal headline value distribution, US$million – regulatory stage

Figure 17: Cancer vaccine deal headline value distribution, US$million – marketed stage

Figure 18: Cancer vaccine deal headline value – median value by stage of development

Figure 19: Cancer vaccine deals with upfront payment values – by stage of development

Figure 20: Cancer vaccine deal upfront value distribution, US$million – discovery stage

Figure 21: Cancer vaccine deal upfront value distribution, US$million – preclinical stage

Figure 22: Cancer vaccine deal upfront value distribution, US$million – phase I stage

Figure 23: Cancer vaccine deal upfront value distribution, US$million – phase II stage

Figure 24: Cancer vaccine deal upfront value distribution, US$million – phase III stage

Figure 25: Cancer vaccine deal upfront value distribution, US$million – regulatory stage

Figure 26: Cancer vaccine deal upfront value distribution, US$million – marketed stage

Figure 27: Cancer vaccine deal upfront payment value – median value by stage of development

Figure 28: Cancer vaccine deals with milestone payment – by stage of development

Figure 29: Cancer vaccine deal milestone value distribution, US$million – discovery stage

Figure 30: Cancer vaccine deal milestone value distribution, US$million – preclinical stage

Figure 31: Cancer vaccine deal milestone value distribution, US$million – phase I stage

Figure 32: Cancer vaccine deal milestone value distribution, US$million – phase II stage

Figure 33: Cancer vaccine deal milestone value distribution, US$million – phase III stage

Figure 34: Cancer vaccine deal milestone value distribution, US$million – regulatory stage

Figure 35: Cancer vaccine deal milestone value distribution, US$million – marketed stage

Figure 36: Cancer vaccine deals with royalty rates-by stage of development

Figure 37: Cancer vaccine deal royalty rate value distribution, US$million – discovery stage

Figure 38: Cancer vaccine deal royalty rate value distribution, US$million – preclinical stage

Figure 39: Cancer vaccine deal royalty rate value distribution, US$million – phase I stage

Figure 40: Cancer vaccine deal royalty rate value distribution, US$million – phase II stage

Figure 41: Cancer vaccine deal royalty rate value distribution, US$million – phase III stage

Figure 42: Cancer vaccine deal royalty rate value distribution, US$million – regulatory stage

Figure 43: Cancer vaccine deal royalty rate value distribution, US$million – marketed stage

Figure 44: Cancer vaccine deal royalty rate payment value – median value by stage of development

Figure 45: Components of the typical cancer vaccine deal structure

Figure 46: Top cancer vaccine deals by value since 2009

Figure 47: Online partnering resources

Figure 48: Forthcoming partnering events

Figure 49: Deal type definitions